PRMT5 and neoplasm: Barczak et al. have shown that pharmacological inhibition of PRMT5 or modulation of E2F1 levels altered the repertoire of ncRNA-derived peptide antigens presented by tumor cells, thus improving their immunogenicity compared to untreated tumor cells.